المؤلفون: Konishi, Kota¹ (AUTHOR), Okamoto, Mamiko¹ (AUTHOR), Tokumitsu, Ryuichi¹ (AUTHOR), Yano, Mitsutake¹ (AUTHOR) yano1210@oita-u.ac.jp, Nasu, Kaei^1,2 (AUTHOR), Kobayashi, Eiji¹ (AUTHOR)

المصدر: Medical Molecular Morphology. Jun2024, Vol. 57 Issue 2, p83-90. 8p.

مصطلحات موضوعية: *IPILIMUMAB, *MELANOMA, *DRUG side effects, *IMMUNE checkpoint inhibitors, *NIVOLUMAB, *PROGRAMMED death-ligand 1, *CESAREAN section

المؤلفون: Mao, Yun‐tao¹ (AUTHOR), Wang, Ying^1,2 (AUTHOR), Chen, Xiao‐Xiao¹ (AUTHOR), Liu, Cheng‐jiang³ (AUTHOR), Bao, Qi⁴ (AUTHOR) baoqi@zju.edu.cn

المصدر: Journal of Cosmetic Dermatology. Apr2024, Vol. 23 Issue 4, p1165-1177. 13p.

مصطلحات موضوعية: *IPILIMUMAB, *IMMUNE checkpoint inhibitors, *DRUG side effects, *CLINICAL trials, *NIVOLUMAB, *MELANOMA

المؤلفون: Won Sang Yoo¹, Eu Jeong Ku², Eun Kyung Lee³ eklee@ncc.re.kr, Hwa Young Ahn⁴ hyahnmd@cau.ac.kr

المصدر: Endocrinology & Metabolism. Dec2023, Vol. 38 Issue 6, p750-759. 10p.

مصطلحات موضوعية: *IMMUNE checkpoint inhibitors, *IPILIMUMAB, *DRUG side effects, *PROGRAMMED death-ligand 1, *ENDOCRINE glands, *ADRENAL insufficiency

المؤلفون: Xie, Wenhui¹ (AUTHOR) xwh828@sina.cn, Xiao, Shiyu^1,2 (AUTHOR), Li, Xiaoyuan^1,3 (AUTHOR), Huang, Jing³ (AUTHOR), Li, Guangtao¹ (AUTHOR), Zhang, Zhuoli¹ (AUTHOR) zhuoli.zhang@126.com

المصدر: European Journal of Internal Medicine. Sep2023, Vol. 115, p88-95. 8p.

مصطلحات موضوعية: *IPILIMUMAB, *IMMUNE checkpoint inhibitors, *ACUTE kidney failure, *DRUG side effects, *CONCOMITANT drugs, *CHRONIC kidney failure

المؤلفون: Changjiang Yang¹, Long Zhao¹, Yilin Lin¹, Shan Wang¹, Yingjiang Ye¹, Zhanlong Shen¹ shenzhanlong@pkuph.edu.cn

المصدر: Cancer Biology & Medicine. Sep2023, Vol. 20 Issue 9, p633-639. 7p.

مصطلحات موضوعية: *IPILIMUMAB, *IMMUNE checkpoint inhibitors, *COLORECTAL cancer, *BIOMARKERS, *TUMOR-infiltrating immune cells, *DRUG side effects

المؤلفون: Kamal, Rayyan Syed^1,2 (AUTHOR), Dean, Arleigh^1,2 (AUTHOR), Dutt, Hanna^1,2 (AUTHOR), Rajeh, Adnan^1,3 (AUTHOR), Fernandes, Ricardo^3,4 (AUTHOR) ricardo.fernandes@lhsc.on.ca

المصدر: Clinical Case Reports. Sep2023, Vol. 11 Issue 9, p1-5. 5p.

مصطلحات موضوعية: *IPILIMUMAB, *TYPE 1 diabetes, *IMMUNE checkpoint proteins, *HYPOGLYCEMIA, *RENAL cell carcinoma, *DRUG side effects

المؤلفون: Xiong, Hao, Shen, Zhu

المصدر: International Journal of Cancer; Jul2024, Vol. 155 Issue 2, p193-202, 10p

مصطلحات موضوعية: DRUG side effects, IMMUNE checkpoint inhibitors, IMMUNOLOGIC memory, IMMUNOTHERAPY, IPILIMUMAB, T cells, PSYCHONEUROIMMUNOLOGY

المؤلفون: Nagasaka, Hirotaka, Kishida, Takeshi, Kouro, Taku, Igarashi, Yuka, Takebe, Shinichi, Yamamoto, Shotaro, Kondo, Takuya, Koizumi, Mitsuyuki, Terao, Hideyuki, Suzuki, Takahisa, Nakaigawa, Noboru, Himuro, Hidetomo, Wei, Feifei, Sasada, Tetsuro

المصدر: International Journal of Clinical Oncology; Jun2024, Vol. 29 Issue 6, p832-839, 8p

مصطلحات موضوعية: IMMUNE checkpoint inhibitors, RENAL cell carcinoma, MATRIX metalloproteinases, PROGNOSIS, IPILIMUMAB, DRUG side effects

المؤلفون: Takada, Ryo, Fujiwara, Miki, Maki, Masatoshi, Nomura, Naoyuki, Kono, Shintaro, Fujita, Akira, Masumoto, Hiroshi, Takahashi, Yoko, Hasegawa, Yasuhisa, Tamura, Koji

المصدر: Journal of Pharmaceutical Health Care & Sciences; 5/31/2024, Vol. 10 Issue 1, p1-8, 8p

مصطلحات موضوعية: DRUG side effects, PATHOLOGIC complete response, RENAL cell carcinoma, NIVOLUMAB, IPILIMUMAB, BREAST

المؤلفون: Kaneko, Ayami, Kobayashi, Nobuaki, Miura, Kenji, Matsumoto, Hiromi, Somekawa, Kohei, Hirose, Tomofumi, Kajita, Yukihito, Tanaka, Anna, Teranishi, Shuhei, Sairenji, Yu, Kawashima, Hidetoshi, Yumoto, Kentaro, Tsukahara, Toshinori, Fukuda, Nobuhiko, Nishihira, Ryuichi, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Kudo, Makoto, Miyazawa, Naoki

المصدر: Thoracic Cancer; May2024, Vol. 15 Issue 15, p1208-1217, 10p

مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, COMBINATION drug therapy, PATIENT safety, DRUG side effects, PATHOLOGIC complete response, PROBABILITY theory, CANCER patients, RETROSPECTIVE studies, IMMUNE system, CANCER chemotherapy, KAPLAN-Meier estimator, DRUG efficacy, RESEARCH, MEDICAL records, ACQUISITION of data, LUNG cancer, NIVOLUMAB, EVIDENCE-based medicine, COMPARATIVE studies, PROGRESSION-free survival, IPILIMUMAB, OVERALL survival, PROPORTIONAL hazards models, EVALUATION